{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T04:04:28Z","timestamp":1750565068066,"version":"3.41.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>After receiving erlotinib for 4 years, a man with advanced lung adenocarcinoma was treated with stereotactic radiotherapy for a left cerebellar brain metastasis. Local relapse of the metastasis was suspected 14 months after and confirmed on <jats:sup>18<\/jats:sup>F-DOPA PET. Three additional uptakes were described with no unequivocal MRI pathological signal. A second radiotherapy course was delivered. One year later, isolated local recurrence was suspected on a 3 T MRI, with a suspicious <jats:sup>18<\/jats:sup>F-DOPA uptake. Five additional <jats:sup>18<\/jats:sup>F-DOPA uptakes were described among which one increased between the 2 PETs. Because of these MRI\/PET mismatches, a switch from erlotinib to osimertinib was preferred over surgery.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005058","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T22:02:15Z","timestamp":1707861735000},"page":"324-326","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Mismatch Between Brain MRIs and 18F-DOPA PET\/CT"],"prefix":"10.1097","volume":"49","author":[{"given":"Vincent","family":"Bourbonne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brieg","family":"Dissaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romuald","family":"Seizeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne","family":"Querellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2013small-cell lung cancer","volume":"353","year":"2005","journal-title":"N Engl J Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S1470-2045(12)70412-6","article-title":"First-line erlotinib in patients with advanced non\u2013small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.radonc.2018.06.039","article-title":"Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases","volume":"130","year":"2019","journal-title":"Radiother Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","year":"2021","journal-title":"Ann Oncol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.3390\/cancers14246264","article-title":"A multi-disciplinary approach to diagnosis and treatment of radionecrosis in malignant gliomas and cerebral metastases","volume":"14","year":"2022","journal-title":"Cancer"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13014-019-1228-x","article-title":"Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review","volume":"14","year":"2019","journal-title":"Radiat Oncol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0","volume":"46","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/cancers15030996","article-title":"Re-irradiation by stereotactic radiotherapy of brain metastases in the case of local recurrence","volume":"15","year":"2023","journal-title":"Cancer"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 \u00d7 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:56Z","timestamp":1750532816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005058"}},"subtitle":["Impact on the Management of a Long Survivor With EGFR-Mutated Lung Adenocarcinoma"],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005058","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,2,9]]}}}